These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23404570)

  • 1. IL-33 causes selective mast cell tolerance to bacterial cell wall products by inducing IRAK1 degradation.
    Sandig H; Jobbings CE; Roldan NG; Whittingham-Dowd JK; Orinska Z; Takeuchi O; Akira S; Bulfone-Paus S
    Eur J Immunol; 2013 Apr; 43(4):979-88. PubMed ID: 23404570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals.
    Ho LH; Ohno T; Oboki K; Kajiwara N; Suto H; Iikura M; Okayama Y; Akira S; Saito H; Galli SJ; Nakae S
    J Leukoc Biol; 2007 Dec; 82(6):1481-90. PubMed ID: 17881510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-33 requires CMRF35-like molecule-1 expression for induction of myeloid cell activation.
    Shik D; Moshkovits I; Karo-Atar D; Reichman H; Munitz A
    Allergy; 2014 Jun; 69(6):719-29. PubMed ID: 24735452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tollip Inhibits ST2 Signaling in Airway Epithelial Cells Exposed to Type 2 Cytokines and Rhinovirus.
    Dakhama A; Al Mubarak R; Pavelka N; Voelker D; Seibold M; Ledford JG; Kraft M; Li L; Chu HW
    J Innate Immun; 2020; 12(1):103-115. PubMed ID: 30928973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-33 is produced by mast cells and regulates IgE-dependent inflammation.
    Hsu CL; Neilsen CV; Bryce PJ
    PLoS One; 2010 Aug; 5(8):e11944. PubMed ID: 20689814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clock-dependent temporal regulation of IL-33/ST2-mediated mast cell response.
    Kawauchi T; Ishimaru K; Nakamura Y; Nakano N; Hara M; Ogawa H; Okumura K; Shibata S; Nakao A
    Allergol Int; 2017 Jul; 66(3):472-478. PubMed ID: 28259547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-33/ST2 signalling and crosstalk with FcεRI and TLR4 is targeted by the parasitic worm product, ES-62.
    Ball DH; Al-Riyami L; Harnett W; Harnett MM
    Sci Rep; 2018 Mar; 8(1):4497. PubMed ID: 29540770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ST2 negatively regulates TLR2 signaling, but is not required for bacterial lipoprotein-induced tolerance.
    Liu J; Buckley JM; Redmond HP; Wang JH
    J Immunol; 2010 May; 184(10):5802-8. PubMed ID: 20400705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells.
    Moulin D; Donzé O; Talabot-Ayer D; Mézin F; Palmer G; Gabay C
    Cytokine; 2007 Dec; 40(3):216-25. PubMed ID: 18023358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2.
    Kawagoe T; Sato S; Matsushita K; Kato H; Matsui K; Kumagai Y; Saitoh T; Kawai T; Takeuchi O; Akira S
    Nat Immunol; 2008 Jun; 9(6):684-91. PubMed ID: 18438411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine mast cells secrete and respond to interleukin-33.
    Tung HY; Plunkett B; Huang SK; Zhou Y
    J Interferon Cytokine Res; 2014 Mar; 34(3):141-7. PubMed ID: 24028396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct post-receptor alterations generate gene- and signal-selective adaptation and cross-adaptation of TLR4 and TLR2 in human leukocytes.
    Li L; Jacinto R; Yoza B; McCall CE
    J Endotoxin Res; 2003; 9(1):39-44. PubMed ID: 12691617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune complex-mediated cell activation from systemic lupus erythematosus and rheumatoid arthritis patients elaborate different requirements for IRAK1/4 kinase activity across human cell types.
    Chiang EY; Yu X; Grogan JL
    J Immunol; 2011 Jan; 186(2):1279-88. PubMed ID: 21160042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal influx of neutrophils in response to IL-33 is mast cell-dependent.
    Enoksson M; Möller-Westerberg C; Wicher G; Fallon PG; Forsberg-Nilsson K; Lunderius-Andersson C; Nilsson G
    Blood; 2013 Jan; 121(3):530-6. PubMed ID: 23093619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and Kit-independent pathways.
    Saluja R; Hawro T; Eberle J; Church MK; Maurer M
    J Biol Regul Homeost Agents; 2014; 28(4):575-85. PubMed ID: 25620169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-33 synergistically enhances immune complex-induced tumor necrosis factor alpha and interleukin-8 production in cultured human synovium-derived mast cells.
    Kashiwakura J; Yanagisawa M; Lee H; Okamura Y; Sasaki-Sakamoto T; Saito S; Tokuhashi Y; Ra C; Okayama Y
    Int Arch Allergy Immunol; 2013; 161 Suppl 2():32-6. PubMed ID: 23711851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-33/ST2 axis promotes mast cell survival via BCLXL.
    Wang JX; Kaieda S; Ameri S; Fishgal N; Dwyer D; Dellinger A; Kepley CL; Gurish MF; Nigrovic PA
    Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10281-6. PubMed ID: 24982172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33.
    Palmer G; Lipsky BP; Smithgall MD; Meininger D; Siu S; Talabot-Ayer D; Gabay C; Smith DE
    Cytokine; 2008 Jun; 42(3):358-64. PubMed ID: 18450470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-33 induces a hyporesponsive phenotype in human and mouse mast cells.
    Jung MY; Smrž D; Desai A; Bandara G; Ito T; Iwaki S; Kang JH; Andrade MV; Hilderbrand SC; Brown JM; Beaven MA; Metcalfe DD; Gilfillan AM
    J Immunol; 2013 Jan; 190(2):531-8. PubMed ID: 23248261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity.
    Supajatura V; Ushio H; Nakao A; Akira S; Okumura K; Ra C; Ogawa H
    J Clin Invest; 2002 May; 109(10):1351-9. PubMed ID: 12021251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.